- Open Access
Self-reported health-related quality of life in persons with HIV infection: results from a multi-site interview project
© Campsmith et al; licensee BioMed Central Ltd. 2003
- Received: 27 March 2003
- Accepted: 24 April 2003
- Published: 24 April 2003
To examine demographic and behavioral associations with self-reported health-related quality of life (HRQOL) among persons with HIV infection or AIDS.
Analysis of interviews with persons ≥ 18 years of age reported through routine disease surveillance with HIV infection or AIDS to nine state and local health departments from January 1995 through December 1996. Scales were constructed from validated measures of HRQOL, and mean scores were calculated (lower scores signified poorer HRQOL). Measures of HRQOL included Overall Health, Pain, Physical Functioning, Role Functioning, Social Functioning, Mental Health, Energy/Fatigue, and Cognitive Functioning. Differences in HRQOL were examined by various demographic and behavioral factors, including taking antiretroviral medication.
HRQOL data were available for 3778 persons. Factors associated with lower HRQOL scores included older age, female sex, black or Hispanic race/ethnicity, injection drug use, lower education and income, no private health insurance, and lower CD4 count. In multivariate analysis, lower CD4 count was the factor most consistently associated with lower HRQOL. Taking antiretroviral medication was not associated with differences in HRQOL regardless of CD4 count.
Perception of HRQOL varied in a population with HIV infection or AIDS. On most HRQOL measures, lower CD4 count was associated with lower HRQOL. Measurement of HRQOL can assist in understanding the long-term effects of disease and treatment on persons with HIV.
- quality of life
- antiretroviral therapy
New antiretroviral therapies introduced in the mid 1990s have allowed many persons with HIV infection to live longer before progressing to AIDS, and to have longer survival following an AIDS diagnosis [1–3]. The annual number of deaths due to AIDS in the United States peaked in 1995 and has since declined , resulting in an increase in the number of prevalent AIDS cases. Current clinical guidelines  call for persons infected with HIV to take a combination of antiretroviral medications to decrease viral load, maintain immune cell function, and prevent the development of resistant viral strains. Thus, for many patients the treatment of HIV has evolved more toward a model of chronic disease management, with patients taking a variety of potent medications for extended periods of time.
Besides clinical outcomes, health-related quality of life (HRQOL) and disability are important issues for persons treated for chronic diseases [6–11], including HIV infection [12–14]. Populations with HIV infection or AIDS have reported different levels of HRQOL, both in clinical trials [15–18] and population-based research [19–21]. We present summary information from a multi-site supplemental surveillance project that describes the levels of HRQOL reported by HIV-infected persons in different demographic and behavioral risk factor groups, stressing the relationship between disease progression and HRQOL.
Since 1990, the Centers for Disease Control and Prevention (CDC) has conducted the Supplement to HIV/AIDS Surveillance (SHAS) Project, an ongoing cross-sectional interview study designed to collect supplemental behavioral surveillance data from persons with HIV infection . Persons 18 years of age or older reported with HIV or AIDS through routine case surveillance were eligible for participation. Participants were enrolled using one of three methods: (1) facility-based recruitment of all eligible persons seeking treatment at selected health care facilities in Atlanta, Connecticut, Denver, Detroit, Florida, and New Jersey; (2) population-based recruitment of all eligible persons in Arizona, Delaware, New Mexico and South Carolina; and (3) population-based recruitment of a 30% sample of men who have sex with men (MSM) and 100% of all other eligible persons in Washington State and Los Angeles County, California. During the period examined for this analysis, Arizona, Denver, Detroit, New Jersey, and South Carolina interviewed persons with HIV infection in addition to those with AIDS. (Three sites-Detroit, South Carolina, and Washington-opted not to collect data using the HRQOL module and were excluded from all analyses.) Informed consent was obtained from all participants prior to the interview, and the study has received institutional review board approval at both the CDC and local levels. Trained interviewers conducted a standardized interview in either English or Spanish that includes questions on demographic characteristics, drug and alcohol use, sexual behaviors, and medical and social service information. Data are self-reported and are not verified through medical record review or clinical tests. On average interviews take approximately 45 minutes to complete. Data were sent to CDC without any personal identifying information.
The format of the SHAS Project allows the questionnaire to be modified to collect data on additional topics of interest. From January 1995 through December 1996, a module of questions adapted from research conducted by Albert Wu and colleagues  was added to study the levels of self-reported HRQOL. Wu et al compiled questions from the RAND Medical Outcomes Study (MOS)  as well as additional items to measure other dimensions of health (energy, distress, and cognitive function) potentially relevant to HIV disease. Wu et al found that their modified health status questionnaire reliably and distinctly measured aspects of health among HIV-positive persons recruited for two clinical trials of zidovudine. HIV-infected persons who were asymptomatic had higher scores on most HRQOL dimensions-indicating relatively less disability and a better quality of life-than persons who were diagnosed with early AIDS related complex.
The SHAS Quality of Life module was used to collect information on self-reported HRQOL in the following dimensions: Overall Health, Pain, Physical Functioning, Role Functioning, Social Functioning, Mental Health, Energy/Fatigue, and Cognitive Functioning. These eight HRQOL dimensions were measured using 24 questions (a subset of the 30 MOS questions used by Wu et al). Response scores for each HRQOL dimension were transformed linearly on scale of 0 to 100. Multi-item dimensions were scored by summing item responses, and internal consistency coefficients (Cronbach's alpha ) were calculated. For each dimension, lower scores indicate relatively lower self-perceived quality of life for that health measure compared to higher scores.
Analysis of variance tests were used to compare crude mean HRQOL scores across demographic and behavioral categories; because the sample was large the significance level for univariate analysis was set at P < 0.01. Multivariate linear regression (least-squares means) was used to identify independent factors associated with HRQOL in the statistical models; analyses included variables noted from the literature as potentially associated with quality of life (e.g., age, sex, education, and income). Linear regression models were then constructed using the separate HRQOL dimension scores as the outcomes; here, the significance level was set at P < 0.05. Tukey-Kramer adjustments for multiple comparisons were used where appropriate. Age and education were included in the models as continuous predictor variables; CD4 count, gender, income, race/ethnicity, mode of exposure, time known to be HIV+, currently taking antiretroviral therapy (yes versus no), and type of SHAS recruitment (population-based versus facility-based) were included as categorical predictor variables. To simplify comparisons across HRQOL dimensions, we report results for models including all predictor variables, regardless of whether any individual variable was predictive of the outcome. All analyses were conducted using SAS Version 6.12 (SAS Institute, Inc., Cary, NC, USA).
From January 1995 through December 1996, 6128 persons were identified for interview at the nine sites that administered the HRQOL module. Of these, 614 were found to have died before they could be contacted. Of the remaining 5514, 4246 (77.0%) completed SHAS interviews, 463 (8.4%) refused to participate, 394 (7.1%) could not be located, and 353 (6.4%) were located but were too ill (either physically or mentally) to participate. Sites phased out the HRQOL module at various times during the two-year period; HRQOL data were available from 3778 interviews. Persons administered the HRQOL module were demographically similar to persons who did not participate in SHAS (refused, could not be located, or too ill), except that a slightly higher percentage of those who did not participate were male (76.0% vs. 73.5%) and white (40.5% vs. 34.0%; chi-square test of proportions, P < 0.001).
Health-related quality of life measures: definitions and the consistency of multi-item measures
Number of Items
Perception of current health
Perception of overall pain
Extent to which health interferes with a variety of activities
Extent to which health interferes with usual daily activities
Extent to which health interferes with normal social activities
General mood or affect, including depression, anxiety, well-being
Extent to which patient felt fatigued
Extent to which reasoning or concentration was impaired
Overall Health score by demographic variables (N = 3778)
HRQOL Measure – Overall Health scorea
Change from reference
Mode of exposure
Other (includes NIR)
Most recent CD4 count
≥ 12 years
Health insurance status
Time HIV+ status known
Current antiretroviral therapy
Type of recruitment
Mean HRQOL scores were stratified across demographic and behavioral categories and compared by using the analysis of variance. As seen in Table 2, lower Overall Health scores were associated with older age, female sex, black or Hispanic race/ethnicity, HIV exposure through injection drug use, lower CD4 count, less than 12 years of education, no private health insurance, and lower income. Mean scores for each of the remaining HRQOL dimensions were also computed and similarly compared by demographic characteristics. In most instances in which significant differences were found, lower HRQOL was associated with the factors already listed (data not displayed).
Adjusted health-related quality of life measures, stratified by CD4 count (N = 3772)
CD4 <200 (n = 1950) (reference)
CD4 200–499 (n = 812)
CD4 ≥ 500 (n = 259)
CD4 Unknown (n = 751)
We were also interested in the relationship between antiretroviral therapy and HRQOL. Most of the study population (65.0%) was currently taking antiretroviral medication. Taking antiretroviral medication differed significantly by CD4 count: 75.1% of those with a CD4 count of <200 were currently taking antiretroviral medication, compared to 68.5% with a CD4 count of 200–499, and 27.3% with a CD4 count of ≥ 500 (P < 0.001, Mantel Hantzel chi-square test for trend). In univariate analysis, current antiretroviral therapy was associated with only two HRQOL dimensions: therapy was negatively associated with Role Function and positively associated with Mental Health. For the dimension of Role Function, currently taking antiretroviral medication was associated with a lower HRQOL score (44.3) than that of persons not currently taking medication (49.8; P < 0.001). However, in the multivariate models examining HRQOL scores stratified by CD4 count, currently taking antiretroviral medication was not associated with differences in HRQOL.
Disability and health-related quality of life are becoming increasingly important issues associated with HIV disease. New developments in the treatment of HIV have produced dramatic improvements in the clinical and immunologic health for many patients, with a resulting reduction in deaths due to AIDS in the United States. Along with clinical indicators of morbidity and mortality, measures of HRQOL (such as physical functioning, mental health, pain, and energy) can help guide treatment decisions for both patients and providers.
Like other researchers, we found that lower HRQOL scores and poorer perception of health were associated with more advanced disease. A majority of the SHAS participants had an AIDS diagnosis at the time of their interview. However, a broad range of CD4 levels is represented in the study population. Both facility-based and population-based strategies were used to recruit SHAS participants. The study population included large numbers of women, racial/ethnic minorities, and persons infected with HIV through injection drug use or heterosexual risk. These groups have not been extensively reported in previous studies of HIV and HRQOL, in which the populations have been more representative of white male clinic patients [16–18, 26–28]. Where significant differences were found by univariate analysis, women, blacks, Hispanics, and persons infected with HIV through injection drug use had lower mean HRQOL scores. However, in multivariate linear regression, sex, race/ethnicity, and HIV infection risk were not associated with differences in HRQOL when stratified by CD4 count.
Several limitations should be considered in the interpretation of our findings. SHAS is a cross-sectional interview study with data self-reported by the participant. Critical indicators of disease progression, such as CD4 count, were not confirmed through clinical testing or review of medical records. Among those who reported having ever had a CD4 count, 12.5% could not recall the most recent CD4 count; on most HRQOL dimensions their scores lay between the scores for the lowest and middle CD4 groups. This finding suggests they were more advanced in their HIV disease; indeed, 83.6% were reported to the national surveillance system as having AIDS. The SHAS questionnaire also did not adequately capture the composition of a person's past and current antiretroviral therapies, or the duration of, and adherence to, those therapies. Specifically, this questionnaire does not assess the effects of protease inhibitor therapy on HRQOL, as those medications were introduced during the period the HRQOL module was used. Of the 2380 persons taking antiretroviral medications at the time of interview, only 39 (1.6%) reported taking protease inhibitors. Although other studies have also reported that questions adapted from the MOS discriminated differences in HRQOL among populations with HIV [15–19], the SHAS questionnaire's shorter 24-item subset of the MOS questions may limit direct comparison of our results with those of other studies. Still, our findings from the HRQOL analysis in SHAS generally agree with those in other published research.
Quality of life issues are also important for persons with HIV as they relate to medication adherence. Complex medication regimens and side effects can affect both quality of life and adherence [29–32]. Resistant viral strains may emerge when adherence to antiretroviral regimens is suboptimal. After the initial HRQOL module was used, the SHAS questionnaire was modified to include questions on use of past and current medications (including protease inhibitors), duration of current therapies, measures of adherence, and reasons for lack of adherence. These questions should provide valuable new data on the relationship of disease progression, therapy, and HRQOL among participants in the SHAS Project.
The evolution toward treatment of HIV disease as a chronic illness presents additional challenges for patients and clinicians. Measures of health-related quality of life can provide important information to behavioral and clinical studies of antiretroviral treatment, adherence, and viral resistance – factors that ultimately influence HIV-related morbidity and mortality.
- Carpenter CC, Fischl MA, Hammer SM, et al.: Antiretroviral therapy for HIV infection in 1998: updated recommendations of the International AIDS Society-USA Panel. JAMA 1998, 280: 78–86. 10.1001/jama.280.1.78PubMedView ArticleGoogle Scholar
- Deeks SG, Smith M, Holodniy M, Kahn JO: HIV-1 protease inhibitors. A review for clinicians. JAMA 1997, 277: 145–153. 10.1001/jama.277.2.145PubMedView ArticleGoogle Scholar
- Saag MS, Schooley RT: Antiretroviral chemotharapy. Current Clinical Topics Infectious Diseases 1998, 18: 154–179.Google Scholar
- Centers for Disease Control and Prevention: HIV/AIDS Surveillance Report 2000,12(2):38–39.Google Scholar
- Centers for Disease Control and Prevention: Guidelines for the using antiretroviral agents among HIV-infected adults and adolescents recommendations of the Panel on Clinical Practices for Treatment of HIV. MMWR 2002,51(RR-7):5–12.Google Scholar
- Lalonde L, Clarke AE, Joseph L, Mackenzie T, Grover SA: Health-related quality of life with coronary heart disease prevention and treatment. J Clinical Epidemiology 2001, 54: 1011–1018. 10.1016/S0895-4356(01)00361-4View ArticleGoogle Scholar
- Janz NK, Janevic MR, Dodge JA, et al.: Factors influencing quality of life in older women with heart disease. Medical Care 2001, 39: 588–598. 10.1097/00005650-200106000-00007PubMedView ArticleGoogle Scholar
- Strand V, Tugwell P, Bombardier C, et al.: Function and health-related quality of life: results from a randomized controlled trial of leflunomide versus methotrexate or placebo in patients with active rheumatoid arthritis. Leflunomide Rheumatoid Arthritis Investigators Group.Arthritis and Rheumatism1999, 42:1870–1878.Publisher Full Text 10.1002/1529-0131(199909)42:9<1870::AID-ANR11>3.0.CO;2-DPubMedView ArticleGoogle Scholar
- Gregg EW, Beckles GL, Williamson DF, et al.: Diabetes and physical disability among older U.S. adults. Diabetes Care 2000, 23: 1272–1277.PubMedView ArticleGoogle Scholar
- Rapp SR, Feldman SR, Exum ML, Fleisher AB Jr, Reboussin DM: Psoriasis causes as much disability as other major medical diseases. Journal American Academy Dermatology 1999, 41: 401–407.View ArticleGoogle Scholar
- Arora NK, Gustafson DH, Hawkins RP, et al.: Impact of surgery on the quality of life of younger women with breast carcinoma: a prospective study. Cancer 2001, 92: 1288–1298. 10.1002/1097-0142(20010901)92:5<1288::AID-CNCR1450>3.0.CO;2-EPubMedView ArticleGoogle Scholar
- Tsevat J, Sherman SN, McElwee JA, et al.: The will to live among HIV-infected patients. Annuals Internal Medicine 1999, 131: 194–198.View ArticleGoogle Scholar
- Call SA, Klapow JC, Stewart KE, et al.: Health-related quality of life and virologic outcomes in an HIV clinic. Quality of Life Research 2000, 9: 977–985. 10.1023/A:1016668802328PubMedView ArticleGoogle Scholar
- Brechtl JR, Breitbart W, Galietta M, Krivo S, Rosenfeld B: The use of highly active antiretroviral therapy (HAART) in patients with advanced HIV infection: impact on medical, palliative care, and quality of life outcomes. Journal Pain & Symptom Management 2001, 21: 41–51. 10.1016/S0885-3924(00)00245-1View ArticleGoogle Scholar
- Wu AW, Rubin HR, Mathews WC, et al.: Functional status and well-being in a placebo-controlled trial of zidovudine in early symptomatic HIV infection. JAIDS 1993, 6: 452–458.Google Scholar
- Bozzette SA, Kanouse DE, Berry S, Duan N: Health status and function with zidovudine or zalcitabine as initial therapy for AIDS. JAMA 1995, 273: 295–301. 10.1001/jama.273.4.295PubMedView ArticleGoogle Scholar
- Cohen C, Revicki DA, Nabulsi A, Sarocco PW, Jiang P: A randomized trial of the effect of ritonavir in maintaining quality of life in advanced HIV disease. Advanced HIV Disease Ritonavir Study Group. AIDS 1998, 12: 1495–1502. 10.1097/00002030-199812000-00012PubMedView ArticleGoogle Scholar
- Revicki DA, Moyle G, Stellbrink HJ: Quality of life outcomes of combination zalcitabine-zidovudine, sasquinavir-zidovudine, and saquinavir-zalcitabine-zidovudine therapy for HIV-infected adults with CD4 cell counts between 50 and 350 per cubic millimeter. AIDS 1999, 13: 851–858. 10.1097/00002030-199905070-00016PubMedView ArticleGoogle Scholar
- Wachtel T, Piette J, Mor V, Stein M, Fleishman J, Carpenter C: Quality of life in persons with human immunodeficiency virus infection: measurement by the medical outcomes study instrument. Annals Internal Medicine 1992, 116: 129–137.View ArticleGoogle Scholar
- Hays RD, Cunningham WE, Sherbourne CD, et al.: Health-related quality of life in patients with human immunodeficiency virus infection in the United States: results from the HIV Cost and Services Utilization Study. American Journal Medicine 2000, 108: 714–722. 10.1016/S0002-9343(00)00387-9View ArticleGoogle Scholar
- Lubeck DP, Fries JF: Health status among persons infected with human immunodeficiency virus. A community-based study. Medical Care 1993, 31: 269–276.PubMedView ArticleGoogle Scholar
- Buehler JW, Diaz T, Hersh BS, et al.: The supplement to HIV/AIDS surveillance project: an approach for monitoring HIV risk behaviors. Public Health Rep 1996,111(Suppl 1):134–137.Google Scholar
- Wu AW, Rubin HR, Mathews WC, et al.: A health status questionnaire using 30 items from the Medical Outcomes Study. Preliminary validation in persons with early HIV infection. Med Care 1991, 29: 786–798.PubMedView ArticleGoogle Scholar
- Stewart AL, Hays RD, Ware JE: The MOS short-form general health survey: reliability and validity in a patient population. Med Care 1988, 26: 724–735.PubMedView ArticleGoogle Scholar
- Cronbach LJ: Coefficient alpha and the internal structure of tests. Psychometrika 1951, 16: 297–334.View ArticleGoogle Scholar
- Weinfurt KP, Wilke RJ, Glick HA, Freimuth WW, Schulman KA: Relationship between CD4 count, viral burden and quality of life over time in HIV-1-infected patients. Med Care 2000, 38: 404–410. 10.1097/00005650-200004000-00007PubMedView ArticleGoogle Scholar
- Low-Beer S, Chan K, Wood E, et al.: Health related quality of life among persons with HIV after the use of protease inhibitors. Quality of Life Research 2000, 9: 941–949. 10.1023/A:1008985728271PubMedView ArticleGoogle Scholar
- Bing EG, Hays RD, Jacobson LP, et al.: Health-related quality of life among people with HIV disease: results from the Multicenter AIDS Cohort Study. Quality of Life Research 2000, 9: 55–63. 10.1023/A:1008919227665PubMedView ArticleGoogle Scholar
- Holzmer WL, Corless IB, Nokes KM, et al.: Predictors of self-reported adherence in persons living with HIV disease. AIDS Patient Care & STDs 1999, 13: 185–197.View ArticleGoogle Scholar
- Bucciardini R, Wu AW, Floridia M, et al.: Quality of life outcomes of combination zidovudine-didanosine-nevirapine and zidovudine-didanosine for antriretroviral-naive advanced HIV-infected patients. AIDS 2000, 14: 2567–2574. 10.1097/00002030-200011100-00020PubMedView ArticleGoogle Scholar
- Swindells S, Mohr J, Justis JC, et al.: Quality of life in patients with human immunodeficiency virus infection: impact of social support, coping style and hopelessness. Int J STD AIDS 1999, 10: 383–391. 10.1258/0956462991914302PubMedView ArticleGoogle Scholar
- Catz SL, Kelly JA, Bogart LM, Benotsch EG, McAuliffe TL: Patterns, correlates, and barriers to medication adherence among persons prescribed new treatment for HIV disease. Health Psychology 2000, 19: 124–133. 10.1037//0278-6126.96.36.199PubMedView ArticleGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article: verbatim copying and redistribution of this article are permitted in all media for any purpose, provided this notice is preserved along with the article's original URL.